Innate Pharma S.A.
IPHYF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $66 | $71 | $84 | $104 |
| Short-Term Investments | $14 | $22 | $17 | $16 |
| Receivables | $2 | $46 | $3 | $1 |
| Inventory | $0 | $0 | -$0 | $0 |
| Other Curr. Assets | $3 | $9 | $35 | $18 |
| Total Curr. Assets | $86 | $148 | $140 | $138 |
| Property Plant & Equip (Net) | $5 | $6 | $9 | $10 |
| Goodwill | $0 | $0 | -$41 | $0 |
| Intangibles | $0 | $0 | $43 | $44 |
| Long-Term Investments | $10 | $10 | $35 | $40 |
| Tax Assets | $0 | $9 | $9 | $5 |
| Other NC Assets | $10 | $2 | $14 | $30 |
| Total NC Assets | $25 | $27 | $68 | $129 |
| Other Assets | $0 | $0 | -$0 | -$0 |
| Total Assets | $111 | $175 | $208 | $267 |
| Liabilities | – | – | – | – |
| Payables | $8 | $9 | $14 | $15 |
| Short-Term Debt | $9 | $9 | $2 | $31 |
| Tax Payable | $7 | $7 | $6 | $7 |
| Deferred Revenue | $1 | $6 | $7 | $13 |
| Other Curr. Liab. | $9 | $9 | $13 | $14 |
| Total Curr. Liab. | $33 | $40 | $41 | $80 |
| LT Debt | $22 | $31 | $40 | $14 |
| Deferred Rev, NC | $3 | $5 | $8 | $25 |
| Deferred Tax Liab, NC | $0 | $9 | $9 | $5 |
| Other NC Liab. | $44 | $39 | $56 | $36 |
| Total NC Liab. | $69 | $84 | $112 | $80 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $1 | $2 | $3 |
| Total Liabilities | $102 | $132 | $154 | $160 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $4 | $4 | $4 | $4 |
| Retained Earnings | -$386 | -$337 | -$330 | -$272 |
| AOCI | $0 | $0 | $1 | $0 |
| Other Equity | $391 | $384 | $380 | $375 |
| Total Equity | $9 | $52 | $54 | $107 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $111 | $184 | $208 | $267 |
| Net Debt | -$35 | -$31 | -$42 | -$60 |